Literature DB >> 16261293

A descriptive evaluation of routine complete blood count monitoring in patients receiving anticoagulation therapy.

Kandace V Anich1, Daniel M Witt, Thomas Delate, Roberta L Shanahan, Rachana J Patel.   

Abstract

CONTEXT: The most prevalent side effect associated with warfarin therapy is bleeding. Routine monitoring of laboratory tests, such as complete blood counts (CBC), may provide theoretical benefit in this patient population as a means of detecting occult bleeding through hemoglobin values that decrease compared to baseline.
OBJECTIVE: To describe the clinical outcomes associated with routine CBC monitoring in a large, diverse sample of anticoagulated patients.
DESIGN: Forty-seven month retrospective, observational study.
SETTING: Large non-profit, group-model health maintenance organization with a centralized clinical pharmacy anticoagulation service that routinely orders baseline CBCs on all patients enrolled in the service with follow up CBCs repeated at 3 months and yearly thereafter. PATIENTS: Patients continuously enrolled in the anticoagulation service for warfarin therapy monitoring for at least one year between January 1, 2000 and December 5, 2003. MAIN OUTCOME MEASURES: Medical records were reviewed to determine clinical outcomes associated with hemoglobin decreases of > or =2.0 gm/dL. Clinical outcomes included both overt and occult bleeding events and a determination of major or minor bleeding in these events.
RESULTS: Of the 4033 patients included in the analysis, 578 (14.3%) experienced at least one decrease in hemoglobin > or =2.0 gm/dL. Occult bleeding was confirmed in 121 patients (3.0% of all patients monitored) with a decrease of hemoglobin > or =2.0 gm/dL but only 13 of these patients (0.3% of all patients monitored) experienced major bleeding. The annual detection rate of occult bleeding through routine CBC monitoring was 0.8%.
CONCLUSIONS: Although routine CBC monitoring provides some utility in detecting occult bleeding, the yield of clinically important decreases in hemoglobin detected was low. For most anticoagulated patients, routine CBC monitoring appears to be clinically unnecessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261293     DOI: 10.1007/s11239-005-3842-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  11 in total

1.  Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication?

Authors:  S A Norton; C P Armstrong
Journal:  Ann R Coll Surg Engl       Date:  1997-01       Impact factor: 1.891

Review 2.  Prosthetic heart valves.

Authors:  W Vongpatanasin; L D Hillis; R A Lange
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

Review 3.  Treatment of hereditary and acquired thrombophilic disorders.

Authors:  W F Baker; R L Bick
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

4.  Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.

Authors:  Daniel M Witt; Melanie A Sadler; Roberta L Shanahan; Georgann Mazzoli; Donald J Tillman
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

5.  A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial.

Authors:  R J Beyth; L Quinn; C S Landefeld
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

6.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

7.  The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.

Authors:  Philip S Wells; Melissa A Forgie; Maureen Simms; Alison Greene; Donna Touchie; Geoffrey Lewis; Jodi Anderson; Marc A Rodger
Journal:  Arch Intern Med       Date:  2003-04-28

8.  Warfarin-associated bleeding complication saved life.

Authors:  Kenneth L McCall; Eric J MacLaughlin
Journal:  Pharmacotherapy       Date:  2002-02       Impact factor: 4.705

Review 9.  Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Mark N Levine; Gary Raskob; Rebecca J Beyth; Clive Kearon; Sam Schulman
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

10.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.